This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Renal Disease and Urology



September 2018

Fedovapagon for nocturia in men with benign prostatic hyperplasia

Fedovapagon works directly in the collecting ducts of the kidney by binding to, and activating receptors that causes the kidneys to reabsorb water from urine as it passes towards the bladder. If fedovapagon is administered before going to bed the result is less urine produced overnight. Therefore, if licensed, fedovapagon would be the first medicinal product specifically for the treatment of nocturia in men with enlarged prostates.


May 2018

Roxadustat for Renal Anaemia in Chronic Kidney Disease

Roxadustat is a product in development that can be taken orally as a tablet. It has the potential to stimulate the growth of red blood cells by increasing the body’s own production of EPO in patients with CKD who may be on dialysis or pre‐dialysis. If approved for the treatment of anaemia in this population, roxadustat will provide an alternative treatment option that offers a likely reduction in the need for supplemental iron as an advantage.


February 2018

Fexapotide Triflutate for Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is a medical term that is used to describe enlargement of the prostate gland. It is not a cancer and is usually not a serious threat to health if well-treated. Most males aged 50 years and above develop BPH.


January 2018

Nefecon (targeted-release budesonide formulation) for IgA Nephropathy (Berger’s disease)

Budesonide is a steroid drug which reduces inflammation. Nefecon is a new oral formulation of budesonide that is designed to specifically deliver the drug to a place in the intestine where most of the immune cells producing IgA are located. This has the potential advantage of targeting the underlying process that causes IgAN with significantly fewer side effects when compared to the generally used systemic steroids such as prednisone, (which is delivered throughout the whole body). If licenced, Nefecon has the potential to become the first disease-specific treatment for IgAN.


September 2017

Pentosan polysulfate sodium (Elmiron) for bladder pain syndrome (interstitial cystitis)

Pentosan polysulfate sodium is the only oral medication that has been developed for bladder pain syndrome. As well as relieving pain and urgency, it is also thought to help to repair the bladder lining. The drug is taken as oral capsules three times a day. If this medicine is launched in the UK, it will …


December 2016

PERiPLEX for the detection of acute infection in peritoneal dialysis

PERiPLEX® is a point-of-care test for the detection of markers of infection (peritonitis) in people undergoing peritoneal dialysis for end stage renal disease. It is designed to be suitable for self-testing. The assay has been developed by Mologic Ltd. and may enable people to test for the presence of acute infection in their own home.


November 2016

Plazomicin for complicated urinary tract infection

Serious infections caused by Gram-negative bacteria are becoming increasingly resistant to commonly prescribed antibiotics and are a serious global concern. If licensed, plazomicin will offer a treatment option for those patients who have a complicated urinary tract infection or acute pyelonephritis caused by multi-drug resistant Gram-negative bacteria, a group who currently have few effective and …


September 2016

Nivolumab (Opdivo) and ipilimumab (Yervoy) for advanced or metastatic renal cell carcinoma – first line

Nivolumab and ipilimumab are two drugs used to treat renal cell carcinoma, which is the most common form of kidney cancer. Many people with kidney cancer show no symptoms for many years and are often diagnosed late, after the cancer has spread. Nivolumab and ipilimumab are delivered straight into the blood and work by altering …


September 2016

Eculizumab (Soliris) for prevention of delayed graft function after kidney transplantation in adult patients at increased risk – first line

Eculizumab is a drug to prevent delayed graft function in people who have undergone a kidney transplant and are at a high risk of this complication. Delayed graft function means the transplant is not working effectively enough and that dialysis is needed within a week of transplantation. Eculizumab is delivered straight into the blood and …


September 2016

InFlow intraurethral valve-pump for atonic bladder

The inFlow™ Intraurethral Valve-Pump (the inFlow™ device) developed by Vesiflo is a nonsurgical urinary device for women with atonic bladder due to impaired detrusor contractility (IDC). The inflow device allows women  with IDC to urinate without the need to catheterise daily or to use an indwelling catheter and urine drainage bag.

Get Alerts